PhaseBio Pharmaceuticals AAQS 2024
PhaseBio Pharmaceuticals AAQS
2
Ticker
PHASQ
ISIN
US7172241090
WKN
A2N7LU
PhaseBio Pharmaceuticals has a current AAQS of 2.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock PhaseBio Pharmaceuticals in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
PhaseBio Pharmaceuticals Aktienanalyse
What does PhaseBio Pharmaceuticals do?
PhaseBio Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for serious metabolic diseases, cardiovascular diseases, and central nervous system diseases. The company was founded in 2002 and is headquartered in Malvern, Pennsylvania, USA. Since its founding, PhaseBio Pharmaceuticals has become one of the leading companies in the industry. PhaseBio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.Frequently Asked Questions about PhaseBio Pharmaceuticals stock
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The PhaseBio Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von PhaseBio Pharmaceuticals
Our stock analysis for PhaseBio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PhaseBio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- PhaseBio Pharmaceuticals Revenue
- PhaseBio Pharmaceuticals Net Income
- PhaseBio Pharmaceuticals P/E
- PhaseBio Pharmaceuticals P/S
- PhaseBio Pharmaceuticals EBIT
- PhaseBio Pharmaceuticals Dividend
- PhaseBio Pharmaceuticals Stocks
- PhaseBio Pharmaceuticals Market capitalization
- PhaseBio Pharmaceuticals Debt
- PhaseBio Pharmaceuticals Liabilities
- PhaseBio Pharmaceuticals Equity
- PhaseBio Pharmaceuticals AAQS
- PhaseBio Pharmaceuticals Employees
- PhaseBio Pharmaceuticals ROE
- PhaseBio Pharmaceuticals ROA
- PhaseBio Pharmaceuticals ROCE